Clinical trial

A Comparison of Proprietary Formulations of Oral Ketamine + Aspirin and Oral Ketamine Alone in Adult Patients Presenting to the ED With Acute Musculoskeletal Pain: Prospective, Randomized, Open-Label, Clinical Trial.

Name
2021-02-02-MMC
Description
Acute Pain is one of the most frequent chief complaints and the main reason for visiting the Emergency Department (ED). The acute pain in the ED is largely prevalent across the country with recent literature demonstrating that 61-91% of patients are admitted to the ED due to a variety of acute painful syndromes. There is a lack of good options for pain control in such settings.
Trial arms
Trial start
2021-04-22
Estimated PCD
2021-11-30
Trial end
2021-12-31
Status
Completed
Phase
Early phase I
Treatment
Aspirin and Ketamine
Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin
Arms:
AOK Group
Oral Ketamine
Proprietary oral formulation of 0.5mg/kg of ketamine
Arms:
OK Group
Size
60
Primary endpoint
Reduction in Pain Score at 60 Minutes
60 minutes
Eligibility criteria
Inclusion Criteria: * Patients age 18 and older * acute musculoskeletal pain * initial pain score of 5 or more on a standard 11- point (0 to 10) numeric rating scale. * awake, alert, and oriented to person, place, and time Exclusion Criteria: * altered mental status, * allergy to aspirin and ketamine, * pregnant * unstable vital signs (systolic blood pressure \<90 or\>180 mm Hg, pulse rate \<50 or \>150 beats/ min, and respiration rate \<10 or \>30 breaths/min) * inability to provide consent * consumption of Aspirin or NSAID's within 6 hours of arrival to the ED * active PUD * history of GI Hemorrhage * history of renal and hepatic insufficiency * past medical history of alcohol or drug abuse * schizophrenia
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 60, 'type': 'ACTUAL'}}
Updated at
2023-04-07

1 organization

2 products

1 indication

Indication
Pain
Product
Ketamine